Minute Insights
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Minute Insight: Abbott Sponsors New Physician Training Program To Diversity Clinical Trial Leadership
The company is partnering with the non-profit organization Women as One and the Global Cardiovascular Clinical Trialists to help train physicians from underrepresented populations to lead clinical trials.
Minute Insight: FDA Clears Fujirebio’s IVD For Alzheimer’s Disease
Fujirebio Diagnostics’ Lumipulse G beta-amyloid ratio test assesses beta-Amyloid pathology in patients with suspected Alzheimer’s disease or other causes of cognitive decline. Lab tests for Alzheimer’s are already available, but this the first in vitro diagnostic for the disease that the agency has authorized.
Minute Insight: Strados Earns FDA 510(k) To Let Patients Use RESP Sensor At Home
The FDA cleared Strados’ RESP sensor to be incorporated into at-home remote monitoring of patients with pulmonary disease in addition to in-hospital monitoring. Strados expects the in-home indication will help physicians better understand their patients’ respiratory health “journey.”
Minute Insight: Guardant Launches Shield Test To Detect Colorectal Cancer In Average-Risk Adults
The Shield lab-developed test was validated in a 309-patient study, demonstrating 91% sensitivity for colorectal cancer. The company is sponsoring the ECLIPSE study to support a PMA for the test.
Minute Insight: Biofourmis Raises $300M To Fund Digital Drug-Companion Therapies
The Boston company will use the new investment to continue scaling its virtual care business. Biofourmis also announced that medtech veteran Omar Ishrak is joining the company’s board as its chairman.
Minute Insight: Phage-Based TB Diagnostic Demonstrates Capability
Actiphage, developed by PBD Biotech could be a key tool in the fight against tuberculosis.
Minute Insight: NHS Employs OCTAPUS AI To Predict Lung Cancer Recurrence
The OCTAPUS AI study demonstrated that machine learning was a better tool than typical assessments used to predict recurrence of non-small cell lung cancer.
Minute Insight: What Is Going On With Butterfly Network’s Leadership?
Since going public, the company’s share price has flopped, its board has seen a flurry of appointments and resignations over the past year, and now the company is facing investor lawsuits.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.